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Abstract: 25 
Drug repositioning offers an effective alternative to de novo drug design to 26 
tackle the urgent need for novel anti-malarial treatments. The anti-amoebic 27 
compound, emetine dihydrochloride, has been identified as a potent in-vitro inhibitor 28 
of the multi-drug resistant strain K1 of Plasmodium falciparum (IC50: 47 nM + 2.1 29 
nM).  Dehydroemetine, a synthetic analogue of emetine dihydrochloride has been 30 
reported to have less cardiotoxic effects than emetine. The structures of two 31 
diastereomers of dehydroemetine were modelled on the published emetine binding 32 
site on cryo-EM structure 3J7A (Pf 80S ribosome in complex with emetine) and it 33 
was found that (-)-R,S-dehydroemetine mimicked the bound pose of emetine more 34 
closely than (-)-S,S-dehydroisoemetine. (-)-R,S-dehydroemetine (IC50 71.03 + 6.1 35 
nM) was also found to be highly potent against the multi-drug resistant K1 strain of 36 
P. falciparum in comparison with (-)-S,S-dehydroisoemetine (IC50 2.07 + 0.26 µM), 37 
which loses its potency due to the change of configuration at C-1´. In addition to its 38 
effect on the asexual erythrocytic stages of P. falciparum, the compounds exhibited 39 
gametocidal properties with no cross-resistance against any of the multi-drug 40 
resistant strains tested. Drug interaction studies showed (-)-R,S-dehydroemetine to 41 
have synergistic antimalarial activity with atovaquone and proguanil. Emetine 42 
dihydrochloride, and (-)-R,S-dehydroemetine failed to show any inhibition of the 43 
hERG potassium channel and displayed activity on the mitochondrial membrane 44 
potential indicating a possible multi-modal mechanism of action.  45 
 46 
 47 
 48 
 o
n
 February 5, 2020 at UNIV O
F SALFO
RD
http://aac.asm
.org/
D
ow
nloaded from
 
3 
 
Introduction: 49 
Malaria presents a huge burden on the economic development of endemic 50 
countries (1). In 2017, WHO reported 219 million malaria cases globally, with an 51 
estimated 435,000 deaths occurring mostly amongst African children. The 20th 52 
century witnessed the development of a range of antimalarials including quinine 53 
alternatives such as mepacrine, chloroquine and primaquine, antifolates such as 54 
sulphadoxine and pyrimethamine, and artemisinin (2) (3) (4) (5) (6) (7). However, the 55 
emergence of resistance against all known classes of anti-malarial drugs including 56 
artemisinin chemotherapy, has warranted research into the development of new 57 
drugs with novel targets against the parasite (8) (9). Drug discovery is hindered by 58 
long development timelines, high attrition rates and soaring R&D costs (10). 59 
Antimalarial chemotherapy has predominantly relied on compounds based on natural 60 
products (11). Emetine dihydrochloride hydrate, a natural product alkaloid derived 61 
from Psychotria ipecacuanha was superseded by the introduction of a safer drug 62 
metronidazole by the 1970s as an anti-amoebic drug (12). Repositioning screens 63 
carried out at the University of Salford, UK, identified emetine dihydrochloride to 64 
have potent, nanomolar in vitro anti-malarial efficacy in the multi-drug resistant K1 65 
Plasmodium falciparum parasite strain. The comparatively significant difference in in 66 
vitro anti-protozoan efficacies (IC50 47 + 2.1 nM in P. falciparum as compared to IC50 67 
26.8 + 1.27 µM in Entamoeba histolytica) dictate that the safety profile for its 68 
repositioned use as an antimalarial could be different (13) (14). The pleiotropic 69 
natural product drug has been reported to have anti-viral and anti-cancer properties, 70 
including recent reports of interrupting viral replication and cell entry for Zika and 71 
Ebola viruses (15). The 40S ribosomal subunit of the eukaryotic 80S ribosome was 72 
recently reported to be the site of action of emetine and is available as a cryo-EM 73 
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structure 3J7A (16). The definition of the target binding site for emetine enables a 74 
chimeric approach to refine using rational design, a drug discovered through 75 
repositioning. 76 
The (R) configuration at C-1´ and the presence of secondary nitrogen at 77 
position 2´ are important for emetine’s biological activity (Fig 1). Indeed, the (S) 78 
configuration at C-1´ (isoemetine) or the substitution of the secondary amine results 79 
in loss of activity. Even if the asymmetry at carbons 2 and 3 are lost with 80 
unsaturation at position 2-3 (2,3-dehydroemetine) the biological activity is retained 81 
(17). In 1980, a study conducted on the cross-resistance of emetine-resistant 82 
mutants of Chinese hamster ovary cells to related compounds found that the 83 
distance between the two aromatic rings and the angle between the nucleophilic 84 
element, such as nitrogen, and the rings were essential for biological activity (18). 85 
Emetine in its crude form has been in use since 1658 for the treatment of 86 
dysentery and was first brought to Europe from Brazil by Piso (19). Powdered 87 
ipecacuanha introduced in Mauritius in 1858 reduced the annual death rate from 88 
severe dysentery from 10-18% to 2% (20). Generalised muscle weakness, vomiting 89 
and cardiotoxicity were the side-effects with prolonged use of emetine (21) (22). A 90 
less emetic and safer synthetic analogue of emetine which could be given as a 91 
resinate 2,3-dehydroemetine, was introduced in 1959 (23). At high doses, the 92 
electrocardiographic changes were similar but were less marked and of shorter 93 
duration. The changes observed in heart conduction, contractility, automaticity and 94 
ECG abnormalities by emetine and 2,3-dehydroemetine could be due to their effect 95 
on membrane permeability to Na+, K+ and, Ca++ ions. Dehydroemetine has been 96 
reported to have less cardio-toxic effects than emetine for the treatment of amoebic 97 
liver abscesses (24) (25) (26).  98 
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 Previous studies have found dehydroemetine was eliminated faster from the 99 
body, and more rapidly from the heart than the liver while reverse was found to be 100 
true for emetine (27). Based on the anecdotal evidence, two diastereomers of 101 
dehydroemetine, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine were 102 
synthesised. Molecular modelling tools (28) (29) were used to predict the activity of 103 
the diastereomers and their potency against the multi-drug resistant K1 strain of P. 104 
falciparum. 105 
Parasites are transmitted from the mammalian hosts to mosquito vectors 106 
through mature Plasmodium gametocytes and hence the reinfection cycle could be 107 
broken with the use of transmission blocking antimalarials (30). Cross-resistance and 108 
gametocidal activity of emetine dihydrochloride and its synthesised analogues were 109 
tested by GSK in a bid to determine the potential of these compounds as 110 
transmission blocking drugs.  111 
A number of studies have reported that dehydroemetine and emetine are 112 
potent inhibitors of protein synthesis (17)(31). It has also been reported that emetine 113 
affects the myocardium in a dose-dependent manner (32). Drugs inhibiting the 114 
cardiac potassium ion channel encoded by the Human ether-a-go-go related gene 115 
(hERG) can prolong the QT interval and cause a dangerous cardiac arrhythmia, 116 
Torsades de pointes, which has hampered a number of drug discovery and 117 
development projects (33). In this study, we tested the activity of emetine 118 
dihydrochloride and its two synthetic analogues against hERG potassium channel.  119 
The three compounds were also tested for any effect on mitochondrial membrane 120 
potential (MMP) as unpublished data from previous studies conducted by our group 121 
predicted atovaquone-like activity on MMP by the parent compound, emetine. 122 
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The preference of combinatorial regimes over monotherapy for the treatment 123 
of malaria has affected the drug discovery pipeline in a crucial way (34). Newer drug 124 
candidates have been tested for synergistic activities with existing antimalarial 125 
treatments for dose reduction to improve therapeutic and safety profiles.  126 
Furthermore, combinatorial regimes expand the shelf-life of the antimalaria drugs by 127 
delaying the emergence of resistance (35) (36). 128 
Chou and Talalay developed a method based on the argument that the issue 129 
of synergy is more physiochemical rather than statistical in nature and employed the 130 
mass-action law principle to derive a median-effect equation where additivity could 131 
be defined using the resulting combination index (CI = 1) with antagonism and 132 
synergism defined as >1 and <1 respectively. CalcuSyn software based on the 133 
complex algorithms for median-effect analysis allows automation and eliminates 134 
subjectivity during data analysis (37). We have previously demonstrated the use of 135 
CalcuSyn as a reliable method to define antimalarial drug interactivity for 136 
combinatorial regimes (38). 137 
Hence, to reduce dose-dependent side effects, combinatorial partner drugs 138 
showing synergistic activity were sought. (-)-R,S-Dehydroemetine was taken forward 139 
for drug interaction studies as it was found to be highly potent against the K1 strain 140 
of P. falciparum. Atovaquone and proguanil were first evaluated to test the efficacy of 141 
the method as the two drugs are known to exhibit synergism (39). The methodology 142 
was then applied to evaluate combinatorial partner drugs for the potent anti-malarial 143 
candidate (-)-R,S-dehydroemetine.   144 
 145 
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Results: 146 
Molecular modelling of ligand interactions with P. falciparum 80S ribosome: 147 
In order to explore the structural basis of the relative inhibitory activity of (-)-148 
R,S-dehydroemetine and (-)-S,S-dehydroisoemetine, we predicted and compared 149 
their molecular interaction with P. falciparum 80S ribosome using computational 150 
docking. As the receptor structure, we use the recently solved cryo-EM structure of 151 
the 80S ribosome of P. falciparum, determined to a resolution of 3.2 Å (16). The 152 
electron density corresponding to the bound emetine is located in the E-site of the 153 
ribosomal small subunit, i.e. Pf40S; this E-site, a binding site that pactamycin also 154 
recognises in the bacterial 30S subunit, is at the interface between 18S rRNA helices 155 
23, 24, 45 and the C-terminus of protein uS11. 156 
On closer examination of the published cryo-EM structure of the complex, the 157 
ligand structure originally modelled into the density, erroneously corresponds to the 158 
non-natural enantiomer of emetine, (1S,2R,3S,11bR)-emetine. This modelled 159 
structure was not the ligand employed in the associated cryo-EM experiments (16). 160 
Therefore, we docked emetine, i.e. the (1R,2S,3R,11bS) structure, into the identified 161 
Pf40S binding site using MOE-Dock [Chemical Computing Group Inc., 1010 162 
Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2016.]. The 163 
docked emetine geometry maps well into the electron density envelope (shown at a 164 
contour level 0.1542e/A^3 (3.50rmsd) in Fig 2a); the bound pose broadly follows the 165 
twisted U-shape conformation of the observed electron density, with improved 166 
alignment in comparison to the previously published non-natural emetine enantiomer 167 
geometry (Fig 2b).  168 
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In this U-shape, an intermolecular T-shaped -stacking interaction is observed 169 
between the two cyclic systems of emetine, i.e. benzo[a]quinolizine rings A/B/C and 170 
isoquinoline rings D/E (Fig 1, Fig 2a). The docked emetine also forges a number of 171 
comparable interactions with the Pf40S subunit as its modelled enantiomer (Fig 2b), 172 
with a key -stacking interaction between the A/B/C rings of emetine with the purine 173 
ring of Gua973 of h23 (16). The location of the emetine secondary and tertiary 174 
amines are broadly similar (within 1 - 2 Å), allowing hydrogen bonding interactions 175 
with a backbone oxygen atom of Ura2061 (h45) and the 2’-hydroxyl group of 176 
Ura1068 (h24) respectively (Fig 2b). The tertiary amine also forms a salt bridge 177 
interaction with the carboxylate side chain of C-terminal residue Leu151 of uS11 (Fig 178 
3b). This interaction was not highlighted in the cryo-EM study and is a consequence 179 
of modelling the natural emetine geometry into the E-site. 180 
Subsequently, the two diastereomers of emetine, (-)-R,S-dehydroemetine and 181 
(-)-S,S-dehydroisoemetine, were docked in turn into the emetine-binding region of 182 
the Pf40S subunit. We found that the preferred docked pose of the (-)-R,S-183 
dehydroemetine adopts the familiar U-shaped conformation, superimposing rather 184 
closely onto the bound pose of emetine (Fig 3a). The docking scores are 185 
correspondingly similar for emetine, with a London dG value of -7.2 kcal/mol, and (-)-186 
R,S-dehydroemetine, which has a dG score of -7.3 kcal/mol. As observed for 187 
emetine, the (-)-R,S-dehydroemetine forms the  stacking interaction with the 188 
Gua973 pyrimidine ring and polar interactions with Ura2061, Ura1068 and Leu151 189 
(Fig 3b).  190 
However, (-)-S,S-dehydroisoemetine docks into the binding site with a lower 191 
dG score of -6.5 kcal/mol and does not overlay in conformation so readily with 192 
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emetine or the (-)-R,S-dehydroemetine (Fig 3a). The particular stereochemical 193 
configuration of (-)-S,S-dehydroisoemetine appears to result in its secondary amine 194 
being more distant from the E-site residues of Pf40S. Consequently, this amine 195 
N…O Ura2061 distance extends by 0.8 Å in proceeding from R to S isomer (Fig 3b). 196 
The tertiary amine interaction with Ura1068 is maintained, however, as is the 197 
interaction with the terminal carboxylate of Leu151 (Fig 3b). The  stacking 198 
interaction with Gua973 is also present, but at a slightly larger distance between 199 
planes, increased by ~0.7 Å. Fig 4 (a) and (b) shows the predicted binding site 200 
residues for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine. 201 
Experimental determination of IC50 to test activity against the K1 strain of P. 202 
falciparum: 203 
Based on the anecdotal evidence, two synthetic analogues of emetine 204 
dihydrochloride, (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine were 205 
synthesised. Experiments to test drug efficacy were set up and (-)-R,S-206 
dehydroemetine was tested in two-fold serial dilutions from 12.5 nM to 200 nM. A 207 
dose response experiment was set up on synchronised ring stage cultures of the K1 208 
strain of P. falciparum to be read at 72 hours. The IC50 of (-)-R,S-dehydroemetine 209 
was observed to be 71.03 + 6.1 nM (Fig 5a). (-)-S,S-dehydroisoemetine was tested 210 
in two-fold serial dilutions from 0.625 µM to 10 µM. The IC50 was observed to be 2.07 211 
+ 0.26 µM concentration (Fig 5b). The figures are derived from representative 212 
experiments performed thrice with each concentration of (-)-R,S-dehydroemetine 213 
and (-)-S,S-dehydroisoemetine tested in triplicates. 214 
 215 
 216 
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Time-course analysis for determination of speed of action of (-)-R,S-217 
dehydroemetine and (-)-S,S-dehydroisoemetine: 218 
Accurate determination of the parasite killing rate in response to treatment is 219 
crucial in the development of drugs against P. falciparum as chemotherapy remains 220 
the primary element in the control of malaria. The speed of action of compounds on 221 
the viability of parasites is difficult to measure through traditional techniques (40). It 222 
is important to identify new drugs with rapid parasite killing kinetics early in the drug 223 
development process. Besides rapid relief of symptoms, a fast-acting drug also helps 224 
to curtail the mutations causing the development of new mechanisms of drug 225 
resistance. In 2012, Tres Cantos developed a labour intensive low-throughput assay 226 
taking up to 28 days to determine in vitro the parasite reduction ratio (PRR) and the 227 
presence or absence of a lag phase in response to a drug (41). The method used in 228 
this study to differentiate between fast and slow acting compounds gives initial 229 
results in 4 to 7 days (42). 230 
The IC50 speed assay was performed for (-)-R,S-dehydroemetine and (-)-S,S-231 
dehydroisoemetine (with concentrations of 25 nM, 50 nM, 100 nM, 200 nM and 400 232 
nM and 0.63 µM, 1.25 µM, 2.5 µM, 5 µM and 10 µM, respectively) using 233 
unsynchronised cultures of P. falciparum. The ratio of 24 hour IC50 values to 72 hour 234 
IC50 values for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine could not be 235 
determined as IC50 could not be reached within 24 hours. Both compounds only 236 
achieved 50% inhibition at the previously defined IC50 values after 48 hours of 237 
exposure, indicating that the isomers have delayed action against the multi-drug 238 
resistant K1 strain of P. falciparum. Fig 6 shows the results for the IC50 speed assay 239 
for (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine respectively (error bars 240 
represent the standard error on the experiments performed twice with each 241 
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concentration of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine tested in 242 
triplicates). 243 
Stage-specific profiling of (-)-R,S-dehydroemetine and (-)-S,S-244 
dehydroisoemetine using synchronised cultures of Plasmodium falciparum: 245 
The two isomers of 2,3-dehydroemetine were tested on synchronous cultures 246 
((-)-R,S-dehydroemetine was tested in two fold serial dilutions from 132.81 nM to 247 
8500 nM and (-)-S,S-dehydroisoemetine was tested in two fold serial dilutions from 248 
3.13 µM to 200 µM) to determine the stage-specificity of the compounds by 249 
measuring the concentration-dependent growth of schizonts and rings following 250 
incubation with the two compounds. 251 
It was observed that (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine 252 
affect both the ring and trophozoite/schizont stages of the parasite. The isomers 253 
were found to be more active in the late trophozoite/schizont stage which is 254 
consistent with the proposed protein synthesis target of the parent compound. They 255 
displayed comparatively less activity against the rings even at high concentrations. 256 
At the highest concentration tested, the growth rate for the rings and 257 
trophozoites/schizonts 24h after the (-)-R,S-dehydroemetine post-exposure wash 258 
was 50.21% and 19.75%, respectively. At the highest concentration tested, the 259 
growth rate for the rings and trophozoites/schizonts 24h after the (-)-S,S-260 
dehydroisoemetine post-exposure wash was 70.98% and 24.67%, respectively. The 261 
lower potency against ring stage parasites may also in part explain the lag-phase 262 
observed during the speed assay, where the IC50 was not reached after 24 hours of 263 
exposure against unsynchronised cultures. 264 
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Fig 7 shows the results for stage-specificity assay for (-)-R,S-dehydroemetine 265 
and (-)-S,S-dehydroisoemetine respectively (error bars represent the standard error 266 
on the experiments performed twice with each concentration of (-)-R,S-267 
dehydroemetine and (-)-S,S-dehydroisoemetine tested in triplicates). 268 
MTT assay for cell cytotoxicity against HepG2 cells: 269 
MTT assay for cell cytotoxicity was performed for (-)-R,S-dehydroemetine and 270 
(-)-S,S-dehydroisoemetine. Emetine and cisplatin were used as control drugs (Fig 8). 271 
The plates were read at 48 hours (43).     272 
Emetine was tested in two-fold serial dilutions from 31.25 nM to 2000 nM with 273 
LD50 observed to be 199.2 + 9.3 nM. (-)-R,S-dehydroemetine was tested in two-fold 274 
serial dilution from 11.72 nM to 750 nM with LD50 observed to be 168.07 + 8.65 nM. 275 
(-)-S,S-dehydroisoemetine was tested in two-fold serial dilutions from 0.312 µM to 10 276 
µM with LD50 observed to be 1.429 + 0.18 µM. Cisplatin was tested in two-fold serial 277 
dilutions from 0.78 µM to 25 µM and with LD50 observed to be 10.16 + 2.6 µM. The 278 
selectivity index, calculated as LD50 HepG2 / IC50 parasites (44), for (-)-R,S-279 
dehydroemetine was 2.37 and (-)-S,S-dehydroisoemetine was observed to be equal 280 
to 0.69. 281 
Determination of cross-resistance through 3H-Hypoxanthine incorporation 282 
assay: 283 
This assay relies on the parasite incorporation of labelled 3H-Hypoxanthine 284 
that is proportional to P. falciparum growth. In-vitro cross-resistance of the 285 
compounds is measured as an IC50 ratio between the IC50 value for the 286 
corresponding P. falciparum strain versus the IC50 value for 3D7A. Every replicate 287 
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from a multidrug-resistant (MDR) strain involved a simultaneous determination using 288 
a 3D7A replicate to avoid any artefact linked to experimental conditions. Table 1 289 
shows the IC50 values of emetine dihydrochloride, (-)-R,S-dehydroemetine and (-)-290 
S,S-dehydroisoemetine in P. falciparum sensitive strain (3D7A) and two P. 291 
falciparum resistant strains (Dd2 and W2). Using 3D7A as a reference, the ratio of 292 
in-vitro cross-resistance of emetine dihydrochloride was found to be 1.15 for Dd2 293 
and 0.77 for W2. The ratio of (-)-R,S-dehydroemetine in both resistant strains, Dd2 294 
and W2, were found to be 1.21 and 1.15 respectively. 295 
The results showed that the inhibitory potency observed for emetine 296 
dihydrochloride and (-)-R,S-dehydroemetine in both multidrug resistant strains (Dd2 297 
and W2) is similar to the sensitive strain 3D7A. These results suggest that there is 298 
no cross-resistance with any of the MDR strains tested. 299 
In-vitro IC50 against P. falciparum male and female activated gametes: 300 
This bioassay assesses the malaria transmission blocking potential of 301 
compounds on NF54 strain by estimating their ability to prevent male mature 302 
gametocytes to progress to male microgametes or/and to inhibit female gamete 303 
activation, as indicators of gametocyte functionality. The NF54 strain was selected  304 
for its increased ability to produce gametocytes under in-vitro conditions (45). The 305 
activation of male gametocytes into mature microgametes is evaluated by the 306 
process of exflagellation (extrusion of rapidly waving flagellum-like microgametes 307 
from the infected erythrocyte). The activation of female gametocytes is evaluated 308 
based on the specific expression of the Pfs25 protein at the surface of the female 309 
activated gametes (46). Male P. falciparum gametocytes exflagellate when activated, 310 
causing the movement of the surrounding RBCs in the media. Detecting these 311 
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changes in cells position, we were able to detect activated male gametes. Female P. 312 
falciparum gametocytes round up when activated and the Pfs25 protein distributes 313 
widely in the membrane of the gamete. Using a monoclonal antibody against this 314 
protein we were able to specifically detect activated female gametes. A Dual Gamete 315 
Formation assay was performed and the results are shown in Table 2. 316 
hERG channel inhibition assay: 317 
Dose-related cardiovascular side-effects observed following treatment of 318 
amoebiasis with emetine include ECG changes such as T-wave inversion, 319 
prolongation of QT interval and widening of the QRS complex and PR interval. 320 
Hypotension, tachycardia and precordial pain were also observed (25). Stoppage of 321 
treatment resulted in complete recovery of cardiovascular functions. Cardiac 322 
microscopic examination revealed a separation of muscle fibres and destruction of 323 
myocardial fibres but an absence of inflammatory cells leading to the interpretation 324 
that the myocarditis is toxic rather than inflammatory in origin. In another study on 325 
thirty two patients, pain was noted at the injection site along with ECG abnormalities, 326 
myalgia, muscle weakness and increased levels of serum creatinine phosphatase 327 
(47). In a study on guinea pigs by Schwartz and Herrero (1965), it was observed that 328 
dehydroemetine was excreted faster than emetine. It was also postulated that 329 
reduced cardiotoxicity of dehydroemetine could be due to decreased tissue affinity to 330 
the heart in comparison to emetine (25).  331 
In a resting cardiac cell, the concentration of K+ is high intracellularly, which 332 
creates a chemical gradient for K+ to diffuse out of the cells. A subunit of the rapid 333 
delayed rectifier potassium ion channel is involved in the cardiac repolarisation (48). 334 
It is encoded by the hERG gene (Human ether-a-go-go related gene). Since emetine 335 
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is known to affect the movements of Na+, K+ and Ca2+ ions, 2,3-dehydroemetine is 336 
also thought to affect ion permeability. HERG channel inhibition assays were 337 
therefore carried out to determine potential influences on the previously observed 338 
cardiotoxicity with emetine therapy.  339 
Data Analysis of hERG channel inhibition assay: 340 
For each replicate the hERG response is calculated using the following 341 
equation: 342 
% hERG response =  
Post − compound current (nA)
Pre − compound current (nA)
 × 100 
The % hERG response was plotted against concentration for the test 343 
compound and, where concentration-dependent inhibition was observed, the data 344 
was fitted to the following equation and an IC50 value calculated: 345 
y =  
ymax − ymin
1 + (
IC50
𝑥 )
s +  ymin 
Where: y = hERG response, ymax = mean vehicle control response, x = 346 
concentration, IC50 = concentration required to inhibit current by 50% and s = Hill 347 
slope 348 
(-)-R,S-dehydroemetine has an IC50 of 19.3 µM for hERG channel whereas (-)-S,S-349 
dehydroisoemetine has an IC50 of 2.99 µM. The IC50 of quinidine which was used as 350 
a positive control is 1.99 µM (Table 3). The selectivity index was calculated as IC50 351 
hERG / IC50 parasites. Thus, it was found that with a selectivity index (SI) of over 352 
271, (-)-R,S-dehydroemetine is not a hERG channel inhibitor, but (-)-S,S-353 
dehydroisoemetine is a potent inhibitor (selectivity index = 1.48).  354 
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Staining with rhodamine123 for measurement of mitochondrial membrane 355 
potential: 356 
Changes in mitochondrial membrane potential were measured using 357 
rhodamine123 (excitation wavelength: 511 nm and emission wavelength: 534 nm), a 358 
membrane permeable cationic fluorescent dye (49), which accumulates by 359 
electrostatic attraction in the mitochondria because of its negative transmembrane 360 
potential. A change in the dye’s concentration in the mitochondria is caused by a 361 
depolarisation event and can be visualised as a shift in fluorescent intensity of 362 
rhodamine123 (50). Draq5 (excitation wavelength: 647 nm and emission wavelength: 363 
>665 nm) is a far-red fluorescent DNA dye which is cell permeable and was used to 364 
distinguish the parasites on flow-cytometry in APC-Cy7-A channel. SYBR Green was 365 
not preferred for this experiment as it emits in the same channel as rhodamine123 366 
and would result in the overlap of emission signals. Fluorescence microscopy was 367 
used to visualise localisation of rhodamine123 within the cytoplasm of the parasites 368 
(Fig 9). 369 
A decrease in fluorescent intensity measured in FITC-A channel indicates a 370 
loss of mitochondrial membrane potential. Atovaquone, a known mitochondrial 371 
inhibitor was used as a control. A shift in fluorescent intensity was observed after 372 
treatment with all three compounds at IC50 and IC50 x 10 concentrations. Emetine 373 
and (-)-R,S-dehydroemetine showed a shift in fluorescent intensity of rhodamine123 374 
in a direction similar to atovaquone indicating a possible mitochondrial effect (Fig 375 
10). Atovaquone produced 41.95% and 43.17% change in mean fluorescent intensity 376 
at IC50 and IC50 x 10 concentrations respectively, emetine produced a change of 377 
31.12% to 35.13% at IC50 and IC50 x 10 concentrations respectively, in a direction 378 
similar to atovaquone and (-)-R,S-dehydroemetine produced a change of 26.76% to 379 
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32.98% at IC50 and IC50 x 10 concentrations respectively, in a direction similar to 380 
atovaquone (Fig 10A). 381 
Validation of the CalcuSyn assay for drug-interaction analysis for malaria: 382 
CalcuSyn method has been validated in our laboratory as a useful tool 383 
antimalarial drug interaction analysis (38). To establish the robustness of the 384 
method, the known synergistic drug combination, atovaquone and proguanil, was 385 
used. Triplicate samples were analysed by SG-plate-reader after 72 hours. In 386 
accordance with published literature, CalcuSyn predicted strong synergism between 387 
the two drugs. 388 
Following validation of the CalcuSyn software using the atovaquone-proguanil 389 
combination, the interaction between (-)-R,S-dehydroemetine-atovaquone and (-)-390 
R,S-dehydroemetine - proguanil were studied. The doses used for each compound 391 
were based on the known ED50 values which served as the midpoint for a two-fold, 392 
constant-ratio dose series as shown in Table 4. 393 
CalcuSyn-based drug-interaction analysis of the atovaquone - proguanil 394 
combination: 395 
The CalcuSyn based analysis of the drug interactivity between atovaquone 396 
and proguanil was carried out using a constant-ratio combination of 1:7000. The 397 
output included a dose-effect curve and a median-effect plot in addition to the 398 
Combination Index (CI) and an isobologram plot, to figuratively depict the 399 
compound’s potency and conformity to the mass action law (Fig 11). Specifically, CI 400 
= 0.20, 0.34 and 0.57 at the ED50, ED75 and ED90 levels (Table 5), respectively were 401 
obtained inferring strong synergism at ED50 and synergism ED75 and ED90. Good 402 
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correlations coefficients of the median-effect plot were reported for atovaquone (r = 403 
0.99), proguanil (r = 0.89), and the combination (r = 0.93), inferring good conformity 404 
to the mass-action law. 405 
CalcuSyn-based drug-interaction analysis for (-)-R,S-dehydroemetine - 406 
atovaquone combination: 407 
The CalcuSyn based analysis of the drug interactivity between (-)-R,S-408 
dehydroemetine and atovaquone using a constant-ratio combination of 25:1 was 409 
done (Fig 12). Specifically, CI = 0.88, 0.88 and 0.89 at the ED50, ED75 and 410 
ED90 levels, respectively were obtained inferring slight synergism at all measurement 411 
points (Table 5). Good correlations coefficients of the median-effect plot were 412 
reported for atovaquone (r = 0.94), (-)-R,S-dehydroemetine (r = 0.94), and the 413 
combination (r = 0.96).  414 
CalcuSyn-based drug-interaction analysis for (-)-R,S-dehydroemetine - 415 
proguanil combination: 416 
The CalcuSyn based analysis of the drug interactivity between (-)-R,S-417 
dehydroemetine and proguanil using a constant-ratio combination of 140:1 was done 418 
(Fig 13). Specifically, CI = 0.67, 1.04 and 1.62 at the ED50, ED75 and ED90 levels, 419 
respectively were obtained implying synergism at ED50, near–additive effect at ED75 420 
and antagonism at ED90 (Table 5). Good correlation coefficients of the median-effect 421 
plot were obtained for proguanil (r = 0.90), (-)-R,S-dehydroemetine (r = 0.86), and 422 
the combination (r = 0.95), suggesting good conformity to the mass-action law. 423 
After 72 hours of incubation, the (-)-R,S-dehydroemetine and atovaquone 424 
interaction was found to show slight synergism at all inhibitory levels analysed. For 425 
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the (-)-R,S-dehydroemetine and proguanil combination the ED50 level of inhibition 426 
was classified as synergism, the ED75 as nearly additive and ED90 as antagonism. 427 
Discussion: 428 
In conclusion, we report here the nanomolar antimalarial efficacy of the synthetic 429 
emetine analogue (-)-R,S-dehydroemetine in the multi-drug resistant K1 strain of 430 
Plasmodium falciparum (IC50 of 71.03 + 6.1 nM). The clinical use of emetine 431 
dihydrochloride as an anti-amoebic drug was superseded by the better tolerated 432 
synthetic analogue 2,3-dehydroemetine in the 1970s. The isomer (-)-S,S-433 
dehydroisoemetine was found to be less potent with an IC50 of 2.07 + 0.26 µM.  434 
Molecular modelling suggests that this greater potency of (-)-R,S-dehydroemetine is 435 
linked to its ability to mimic more fully the interactions of emetine with the E-site of 436 
Pf40S subunit, compared to the (-)-S,S-dehydroisoemetine isomer. The 437 
improvements in the dose-dependent cardiotoxicity previously reported for 2,3-438 
dehydroemetine in comparison to emetine dihydrochloride was linked to decreased 439 
affinity to cardiac myocytes and increased clearance from the body (27). We propose 440 
that the very significant differential in-vitro activities of emetine dihydrochloride in 441 
Entamoeba histolytica (IC50 26.8 + 1.27 µM) and Plasmodium falciparum (IC50 47 + 442 
2.1 nM) (13) (14) would mean that the dose related toxicity profile for its re-443 
positioned use will be different.   444 
Analysis done by GSK showed that in asexual blood stages, the compounds 445 
exhibited no cross-resistance issues. Mosquito vector dynamics, the number of 446 
people with peripheral gametocytaemia in the population, and the infectiousness of 447 
circulating gametocytes to mosquitoes determines the transmission of malaria. 448 
Interrupting transmission is an important aspect of preventing malaria in endemic 449 
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areas and there has been renewed interest in compounds preventing the formation 450 
of gametocytes. (-)-R,S-dehydroemetine was found to be gametocidal. It displayed 451 
activity against both male and female gametes. Thus, it also has the potential to 452 
block the transmission of malaria.  453 
The selectivity indices calculated using MTT assays in HepG2 cell lines was similar 454 
for emetine and its analogues. It is important to note that the low selectivity index 455 
was expected given the documented anticancer properties of emetine (51). This 456 
could explain the low LD50 obtained on Hep G2 lines as these are rapidly multiplying 457 
cancer cell lines. The selective advantage of (-)-R,S-dehydroemetine for cardiotoxic 458 
effects is linked to its faster elimination from body, hence the appropriate toxicity 459 
investigation to define this would be the use of in vivo animal models. It is imperative 460 
to progress this work in this direction. It was also clearly established that the cardiac 461 
toxicity for (-)-R, S-dehydroemetine was not effected through the hERG channel.  462 
Our observations suggest that emetine and its two synthetic analogues produces 463 
changes in the mitochondrial membrane potential at IC50 concentrations, indicating a 464 
possible multi-modal mechanism of action.  465 
The failure of monotherapy has been unambiguously demonstrated in malaria, 466 
hence, the forceful insistence by the WHO for the use of artemisinin-based 467 
combination therapy (ACT) as a policy standard. In addition to more potent 468 
therapeutic efficacies, other benefits of combination regimes include decreased 469 
toxicity, favourable synergistic interactions and most significantly, the potential to 470 
impede or delay the onset of resistance. Drug interaction analysis presented here 471 
emphasises a route to further dose reduction to minimise toxicity. (-)-R,S-472 
dehydroemetine was found to exhibit synergistic activity with proguanil and display 473 
slight synergism with atovaquone.  474 
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Emetine and its analogues, constitute a pleiotropic group of natural product-derived 475 
compounds which could potentially enhance the depleted antimalarial 476 
armamentarium, should a catastrophic gap in the drug market occur as a result of 477 
the spread of resistance to frontline antimalarials. The work presented here provides 478 
strong justification for further optimisation, particularly for use in a hospital setting in 479 
cerebral malaria, where appropriate monitoring could obviate progression of the 480 
reversible cardiotoxicity previously reported. Its hepatic concentration ability could 481 
indeed have favourable consequences for the treatment of Plasmodium vivax 482 
infections. The history of antimalarial chemotherapy has been largely reliant on 483 
natural product-derived leads. We provide here a significant body of evidence to 484 
progress and further optimise a previously overlooked, potent and affordable natural 485 
product compound.    486 
Materials and Methods: 487 
Culture of Plasmodium falciparum 488 
RPMI 1640 media containing 25 mM HEPES and 0.3 g/L L-glutamine (Gibco, 489 
Life Technologies, UK) supplemented with sterile filtered 2.5 g Albumax (Sigma, 490 
UK), 2.5 ml hypoxanthine (Sigma, UK), 2.5 ml 40% glucose (Dextrose Anhydrous, 491 
Fisher Scientific, UK) and 0.5 ml gentamycin (Sigma, UK), were used for the culture 492 
of erythrocytic stage, strain K1, P. falciparum parasites (gifted by Prof John Hyde, 493 
University of Manchester, UK, original source: Thai-K1 clone), under a 5% CO2 5% 494 
O2 and 90% N2 gas mixture (BOC Limited, UK) at 37
oC. All routine culture methods 495 
were consistent with those employed by (52). 496 
O+ human blood (purchased from NHS Blood Bank, Manchester, UK) was 497 
used routinely to maintain the parasites. Continuous cultures were maintained at 5% 498 
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haematocrit.  Since synchronous parasite development is observed in natural hosts 499 
and this synchrony is lost quite rapidly in in-vitro cultures, sorbitol was used to keep 500 
the parasites in tight synchrony. In brief, the parasitized blood pellet was re-501 
suspended  1:10 in 5 % sorbitol (prepared in distilled water and filtered using 0.22 502 
µm porosity Millipore filter), incubated at room temperature for 5 minutes and then 503 
centrifuged at 3000 rpm for 5 minutes. The supernatant was removed and complete 504 
media was used to wash the pellet 3 times before setting up a new culture.  505 
Synthesis of (-)-2,3-Dehydroemetine: 506 
(-)-2,3-Dehydroemetine was synthesised as per the established literature 507 
(Brossi 1967, Patent No. 3,311633 [16]). The synthesis was outsourced to 508 
Chiroblock GMBH, Germany. Previously published patent literature by chemists at 509 
Hoffmann-La Roche did not include modern analytical data such as mass 510 
spectrometry or NMR. The methodology adopted for the synthesis (-)-R,S-511 
dehydroemetine 7 used in this study followed the published patent with minor 512 
modifications as depicted in Fig 14. 513 
The two compounds synthesised were (-)-R,S-dehydroemetine, 7, and (-)-514 
S,S-dehydroisoemetine, 8. Briefly, the Mannich base 1 was quaternized and reacted 515 
with the imine 2 giving piperidinone 3 as an approximately 5:1 mixture of 516 
diastereomers which were not separated. Knoevenagel condensation with 517 
malononitrile led to unsaturated dinitrile 4 in 69% yield. Hydrolysis and 518 
decarboxylation, with concomitant alekene isomerization, gave 5 after methylation. 519 
Resolution with (+)-dibenzoyl-D-tartaric acid gave homochiral (-)-5. Hydrolysis and 520 
amidation with homoveratrylamine followed by Bischler–Napieralski cyclization led to 521 
dihydroisoquinoline derivative 6, also known as 2-dehydro-O-methyl psychotine. The 522 
 o
n
 February 5, 2020 at UNIV O
F SALFO
RD
http://aac.asm
.org/
D
ow
nloaded from
 
23 
 
cyclic imine was reduced with sodium borohydride in methanol to give a 1:1 mixture 523 
of the desired 2,3-dehydroemetine 7 and 2-dehydroisoemetine dihydrobromide 8, 524 
separated by fractional crystallization. The purity of (-)-R,S-dehydroemetine obtained 525 
through this method was 85% with the balance consisting of the diastereomer, 8. 526 
Molecular modelling:  527 
In preparation for predicting the bound pose of emetine, (-)-R,S-528 
dehydroemetine and (-)-S,S-dehydroisoemetine, the cryo-EM structure of P. 529 
falciparum 80S ribosome bound to emetine dihydrochloride was obtained from the 530 
Protein Data Bank (PDB code 3J7A) (16). We note that this cryo-EM structure 531 
features the enantiomer of emetine rather than emetine itself; therefore, an initial 3D 532 
structure of emetine was obtained from the OMEGA-generated conformer in the 533 
Pubchem database (53). Subsequently emetine derivatives (-)-R,S-dehydroemetine 534 
and (-)-S,S-dehydroisoemetine were constructed using the software package MOE 535 
(54). Prior to in silico docking, crystallographic water molecules and a magnesium 536 
ion were removed (the latter was within 13 Å of the active site and was found to 537 
unduly influence docking solutions). Hydrogens were assigned consistent with 538 
physiological pH. Docking of ligands to the Pf40S subunit was performed using 539 
MOE-Dock[Chemical Computing Group Inc., 1010 Sherbrooke St. West, Suite #910, 540 
Montreal, QC, Canada, H3A 2R7, 2016]. The binding site region was defined using 541 
the cryo-EM ligand location. Ligand placement used the Triangle Matcher protocol. 542 
Internal flexibility was permitted for ligands but not ribosome. Poses were scored via 543 
the London dG scoring function. While this docking protocol was able to reproduce 544 
well the cryo-EM pose of the emetine stereoisomer bound to the Pf40S subunit (S1 545 
Figure, Supporting Information), please see comment later regarding this ligand’s 546 
structure.  547 
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Drug preparation: 548 
Emetine dihydrochloride was obtained from Sigma Aldrich, UK. The 549 
dehydroemetine analogues were synthesised as per the established literature 550 
(Scheme 1, Brossi 1967, Patent No. 3,311633 [16]). Derivatives were validated using 551 
NMR, HPLC and FTIR. The synthesis process was outsourced to Chiroblock GMBH, 552 
Germany. Drug stock solutions were prepared in DMSO in accordance with 553 
manufacturer instructions and primary stock concentration of 5 mM was aliquoted 554 
and stored at -20oC until further use. Serial dilutions of the working solution were 555 
made using complete media for the experiments. 556 
Experimental determination of IC50 to test activity against the K1 strain of P. 557 
falciparum: 558 
Refined dose ranges were selected for emetine dihydrochloride (12.5 nM – 200 nM), 559 
(-)-R,S-dehydroemetine (12.5 nM - 200 nM), and (-)-S,S-dehydroisoemetine (0.625 560 
µM - 10 µM) to permit accurate IC50 calculation against the K1 strain of P. 561 
falciparum. Ring stage parasites were diluted to 0.5-1% parasitaemia, 2.5% 562 
haematocrit (in a 96 well plate format, 200 µl final well volume) and treated for 72 563 
hours. Dose response parasitaemia was determined using the SYBR Green-based 564 
flow cytometer or plate-reader method previously optimised in the laboratory (14). 565 
SYBR Green staining of erythrocytic stage P. falciparum for flow cytometry: 566 
Following drug efficacy experiments, 150 µl from the control and drug-treated 567 
wells on a 96 well plate were transferred to a microcentrifuge tube and samples were 568 
washed once with PBS. The supernatant was removed and samples were incubated 569 
in the dark at room temperature for 20 minutes following addition of 1 ml of 5 x SYBR 570 
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Green solution (prepared by adding 5 µl of 10,000 x SG to 10 ml PBS). After 571 
staining, the samples were centrifuged for 1 minute at 14,000 rpm and the 572 
supernatant was discarded. Samples were re-suspended in 250 µl of 0.37% 573 
formaldehyde fixation solution prepared by diluting 36.5% formaldehyde (Sigma, UK) 574 
with PBS to a final concentration of 0.37%. The samples were placed in the fridge 575 
and incubated at 4℃ for 15 minutes. Subsequently, PBS was used to wash the 576 
samples 3 times and finally the samples were suspended in 1 ml PBS. Parasitaemia 577 
was determined by SYBR green fluorescence using the FITC channel of the BD 578 
FACsVerse flow cytometer system (Blue laser, excitation laser line 488 nm 579 
EXmax 494 nm/Emmax 520 nM) and cell size (forward scatter, FSC-A). Fifty thousand 580 
events were recorded and in three replicates for each. Fluorescent events in drug-581 
treated samples were compared with infected and uninfected blood counterparts and 582 
gated accordingly to obtain the percentage parasitaemia.  583 
Time-course analysis through IC50 speed assay using unsynchronised cultures 584 
of Plasmodium falciparum: 585 
The assay was used to determine the speed of action of the emetine 586 
analogues. Unsynchronised cultures of K1 strain P. falciparum was used and 587 
parasites were grown in presence of (-)-R,S-dehydroemetine and (-)-S,S-588 
dehydroisoemetine for three incubation periods of 24 hours, 48 hours and 72 hours. 589 
The assays were analysed by determining SYBR green fluorescence as described 590 
above in the methodology.  591 
 592 
 593 
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Stage-specific profiling of (-)-R,S-dehydroemetine and (-)-S,S-594 
dehydroisoemetine using synchronised cultures of Plasmodium falciparum: 595 
Parasite cultures with ≥ 80% trophozoites and ≥ 80% rings were obtained by 596 
synchronisation with 5% Sorbitol (42). The cultures were synchronised twice, at 0 597 
hours and 31 hours to obtain young rings which were up to 3 hours old. To obtain 598 
early schizont stages, the culture was synchronised twice with the second 599 
synchronisation being 6 to 8 hours after the first.  Each synchronous stage was 600 
incubated for 24 hours at 37 °C on a 96-well microtitre plate with a two-fold serial 601 
dilution of the drugs ranging from 1.6 to 100 fold the IC50 of each drug. The plates 602 
were washed 4 times after the incubation in order to dilute the drug concentration by 603 
> 1000 fold. The plates were incubated for another 24 hours at 37°C following which 604 
SYBR green staining was used to read the plates as described above.  605 
MTT assay for cell cytotoxicity against HepG2: 606 
HepG2 cells (University of Salford stocks purchased from American Type 607 
Culture Collection (ATCC), USA), were grown in media consisting RPMI 1640, 2 mM 608 
L-Glutamine, HEPES, 10% foetal bovine serum, 1% non-essential amino acids and 609 
1% penicillin-streptomycin. Cells were calculated on a haemocytometer to make a 610 
new cell-media solution to a concentration of 5000 cells/100 µl and 100 µl of this new 611 
cell solution was added into each well of the 96 well plate. After 24 hours incubation, 612 
100 µl of the drug prepared in the media were added to the wells. This was repeated 613 
in triplicate and the plate was incubated for a further 48 hours (55). After the 614 
incubation period, 50 µl of MTT solution was added to each well and incubated for 3 615 
hours. The liquid in each well was aspirated carefully and 200 µl of DMSO was 616 
added to each well and results were read on the Ascent plate reader.  617 
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Derivation of dose-response curves and IC50 values:  618 
The infected blood controls were set at 100% for normalisation and 619 
percentage parasitaemia was calculated for drug treated samples relative to the 620 
infected control. For IC50, GraphPad prism 5.0 was used to further process the data. 621 
IC50 values were calculated using nonlinear regression (GraphPad prism 5.0) by 622 
using log-transformed drug concentrations plotted against the dose response. The 623 
log(inhibitor) vs. Normalised response-Variable slope option was used for IC50 624 
calculation. Emetine dihydrochloride was used as a control drug to validate the 625 
method. 626 
Determination of cross-resistance through IC50 determination in multidrug 627 
resistant P. falciparum strains (carried out at Tres Cantos, GSK): 628 
The three strains used for the assay were 3D7A, Dd2 and W2 based on their 629 
resistance profiles. 3D7A is chloroquine–sensitive, Dd2 is resistant to chloroquine, 630 
mefloquine and pyrimethamine (56) and W2 is resistant to chloroquine, quinine, 631 
pyrimethamine, cycloguanil, and sulfadoxine (57) (from the Malaria Research and 632 
Reference Reagent Resource Center MR4). A culture of parasitized red blood cells 633 
(RBC) of the corresponding strain, (0.5% parasitaemia, 2% haematocrit) in RPMI-634 
1640, 5% albumax and 5 µM hypoxanthine was exposed to 9 dilutions (3-fold serial 635 
dilutions) of the compound starting at 5 µM. 100 µl of culture volume was plated in 636 
96-well flat bottom microtiter plates + 0.5 µl drug (stock x200 in DMSO). Plates were 637 
incubated for 24 h at 37 ºC, 5% CO2, 5% O2, 90% N2. Next, 3H-Hypoxanthine was 638 
added and plates were incubated for another 24 h period. After that, parasites were 639 
harvested on a glass fibre filter using a TOMTEC Cell harvester 96. Filters were 640 
dried and melt-on scintillator sheets were used to determine the incorporation of 3H-641 
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Hypoxanthine. Radioactivity was measured using a microbeta counter. Data are 642 
normalized using the incorporation of the positive control, (parasitized red blood cells 643 
without drug). IC50 values were determined using Grafit 7 program (41). 644 
Determination of transmission blocking potential through in vitro inhibition of 645 
gamete activation 646 
Asexual cultures of P. falciparum NF54 strain parasites were used to seed 647 
gametocyte cultures at 0.5% parasitaemia, 4% haematocrit in 50 ml total volume 648 
under 3% O2/ 5% CO2/ 92% N2 gas. Culture medium (RPMI 25 mM HEPES, 50 mg/l 649 
hypoxanthine, 2 g/l NaHCO3 without L-glutamine + 5% human serum and 5% 650 
Albumax) was replaced daily for 14 days. At day 14, the concentration of non-651 
purified cultures was adjusted to plate 700.000 total cells per well in each 384-well 652 
plate. The test drugs were then added in two-fold serial dilutions starting at 10 µM 653 
(10 µM – 0.00976 µM) and incubated 48 h at 37 ºC (3% 02, 5% CO2, 92% N2). 654 
DMSO was used as the negative control and Thiostrepton as the positive control. 655 
Activation was performed with ookinete medium (Same RPMI base used for culture 656 
but supplemented with xanthurenic acid 50 µM) supplemented with the antibody anti-657 
Pfs25-Cy3 at a final concentration of 1/2000 (from 1 mg/ml stock). Plates were 658 
analysed to detect exflagellation centres. "Triggered" cultures were then incubated 659 
(protected from light) at 26 °C for 24 h (in a thermoregulated incubator). Then, plates 660 
were analysed to detect female activated gametes. Activation of male gametes was 661 
detected based on light changes provoked by flagella movements which caused 662 
movement of surrounding cells. A 10-frame video was taken and then analysed to 663 
determine these changes in cell position based on pixels change. Then, the script 664 
determined where exflagellation centres were located, based also on size and 665 
intensity of light changes. Activation of female gametes was based on detection of 666 
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fluorescent Cy3-Anti Pfs25 antibody (as the primary parameter) followed by a 667 
selection of events according to their size, roundness and the intensity of the 668 
fluorescence. Both measurements were performed using automated inverted 669 
microscope Ti-E Nikon using JOBS software. Analysis of images and videos was 670 
performed with the ICY program. The IC50 value was determined using Microsoft 671 
Excel and GraphPad. 672 
hERG Channel Inhibition (IC50 Determination) assay Protocol: 673 
The experiment to test the potential of emetine, (-)-R,S-dehydroemetine and (-674 
)-S,S-dehydroisoemetine to inhibit hERG channel was outsourced to Cyprotex, UK. 675 
100 µl of a 20 mM concentration of all three compounds in DMSO was provided to 676 
Cyprotex. Compound dilutions were prepared by diluting a DMSO solution (default 677 
10 mM) of the test compound using a factor 5 dilution scheme into DMSO, followed 678 
by dilution into extracellular buffer such that the final concentrations tested are 679 
typically 0.008, 0.04, 0.2, 1, 5, 25 µM (final DMSO concentration 0.25%). Chinese 680 
Hamster Ovary cells expressing the hERG potassium channel were dispensed into 681 
384-well planar arrays and hERG tail-currents were measured by whole-cell 682 
voltage-clamping. Amphotericin B was used as a perforating agent is circulated 683 
underneath the PatchPlateTM to gain electrical access to the cell. The pre-compound 684 
hERG current was measured. Emetine, (-)-R,S-dehydroemetine and (-)-S,S-685 
dehydroisoemetine in a range of concentrations were then added to the cells and a 686 
second recording of the hERG current was made. The test compound was left in 687 
contact with the cells for 300 sec before recording currents. Quinidine, an 688 
established hERG inhibitor, was included as a positive control, and vehicle control 689 
(0.25% DMSO) as the negative control. All buffers, cell suspensions and drug 690 
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compound solutions were at room temperature. The percent change in hERG current 691 
was measured and used to calculate an IC50 value. 692 
Each concentration was tested in 4 replicate wells on the PatchPlateTM 693 
(maximum of 24 data points). It was ensured that only acceptable cells were used to 694 
assess hERG inhibition by applying filters.  The cell must maintain a seal resistance 695 
of greater than 50 MOhm and a pre-compound current of at least 0.1 nA, and ensure 696 
cell stability between pre-and post-compound measurements. 697 
Staining with rhodamine123 for mitochondrial membrane potential disruption: 698 
Rhodamine123 and draq5 were used to observe the effect of emetine and its 699 
two synthetic analogues on mitochondrial membrane potential. Rhodamine123 is a 700 
mitochondrial specific dye which emits in FITC channel on flow-cytometry whereas 701 
draq5 stains the DNA and emits in APC-Cy7-A channel. The two dyes were chosen 702 
to perform the experiment as there is very minimal overlap in their emission signals. 703 
Synchronised culture of P. falciparum K1 strain at trophozoite stage was incubated 704 
with 1 ml of 200 nM Rhodamine123 for 1 hour, followed by a further incubation with 705 
100 µl of 10 µM Draq5 for 20 mins. Smears prepared after the incubation were 706 
immediately viewed under the fluorescence microscope at 100 x magnification to 707 
visualise localisation of the dyes inside the parasite. 708 
To test the effect of emetine and its analogue on mitochondria, synchronised 709 
cultures of P. falciparum K1 strain at trophozoite stage were incubated at 2.5% 710 
haematocrit (in a 96 well plate format, 200 µl final well volume) for 2 hours with IC50 711 
and IC50 x 10 concentrations of atovaquone, emetine hydrochloride and (-)-R,S-712 
dehydroemetine. Compounds were then washed away by centrifuging the cultures 713 
and a pellet was prepared for each drug concentration. Pellets were then incubated 714 
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with 1 ml of 200 nM rhodamine123 for 1 hour, followed by a further incubation with 715 
100 µl of 5 µM draq5 for 20 mins. After a wash with PBS, the experiment was read 716 
with flow-cytometer on FITC channel. Loss of mitochondrial membrane potential was 717 
indicated by a decrease in fluorescent intensity. 718 
Drug interaction analysis for (-)-R,S-dehydroemetine: 719 
Primary stock solutions were prepared as mentioned above. For experimental 720 
set up the primary stock solutions were further diluted with complete medium to give 721 
final test concentrations. A dose range of 0.125–8 x the ED50 was made by a two-722 
fold serial dilution for atovaquone, proguanil, and (-)-R,S-dehydroemetine. For 723 
atovaquone, the doses ranged from 0.25nM to 16nM for combination with proguanil, 724 
and 0.5 nM to 32 nM for combination with (-)-R,S-dehydroemetine. For proguanil the 725 
doses ranged from 1.75 µM to 112 µM. For (-)-R,S-dehydroemetine the doses 726 
ranged from 12.5 nM to 800 nM. At each level, the compounds were co-administered 727 
for example ED50 of atovaquone was combined with the ED50 of (-)-R,S-728 
dehydroemetine and 2 x ED50 atovaquone was combined with 2 x ED50 (-)-R,S-729 
dehydroemetine and so forth. Parasites were treated at ring stage and incubated for 730 
72 hours in a 96 well plate format. The SYBR Green Plate reader method was used 731 
to determine drug susceptibility. The data was analysed for the median-effect using 732 
CalcuSyn software (Biosoft) by converting triplicate data to an averaged percentage. 733 
The r values are also reported for all sets of data. The r value represents the linear 734 
correlation coefficient for the median effect plot and indicates conformity to the mass 735 
action law. The CalcuSyn software generates the CI over a range of fa levels at 736 
different growth inhibition percentages. The interpretation of CI was done in 737 
accordance with table 6 (37).  738 
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Figures: 935 
Figure 1 936 
 937 
Fig 1: Structure of emetine hydrochloride. 938 
 939 
 940 
 941 
 942 
 943 
 944 
 945 
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Figure 2 946 
 947 
Fig 2 (a) Overlay of the docked pose of emetine (green) with its enantiomer present 948 
in the cryo-EM structure (maroon); observed electron density envelope is also shown 949 
(wireframe surface with contour level 0.1542e/A^3 (3.50rmsd)); (b) Interactions of 950 
docked emetine (green) with Pf40S residues and comparison with previously 951 
modelled interactions of its enantiomer (blue) (16). 952 
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Figure 3 953 
 954 
Fig 3 (a) Overlay of docked poses of (-)-R,S-dehydroemetine (red) and (-)-S,S-955 
dehydroisoemetine (cyan) with emetine (blue). (b) Interactions of (-)-R,S-956 
dehydroemetine (red) and (-)-S,S-dehydroisoemetine (cyan) with the Pf40S binding 957 
site. Distances (dotted lines) in Å. 958 
 959 
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Figure 4 960 
 961 
Fig 4 (a) Docking through MOE showing the binding site residues for (-)-R,S-962 
dehydroemetine molecule. (b) Docking through MOE showing the binding site 963 
residues for (-)-S,S-dehydroisoemetine molecule. 964 
 965 
 966 
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 968 
 969 
 970 
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Figure 5 971 
 972 
Fig 5: (a) The effective dose of (-)-R,S-dehydroemetine (dose range tested in two-973 
fold serial dilutions from 12.5 nM to 200 nM) on P. falciparum (K1) infection after an 974 
incubation period of 72 hours using SYBR Green-based plate-reader assay. (b) The 975 
effective dose of (-)-S,S-dehydroisoemetine (dose range tested in two-fold serial 976 
dilutions from 0.625 µM to 10 µM) on P. falciparum (K1) infection after an incubation 977 
period of 72 hours using SYBR Green-based plate-reader assay. The experiments 978 
were performed thrice with each concentration of (-)-R,S-dehydroemetine and (-)-979 
S,S-dehydroisoemetine tested in triplicates). Data were analysed using GraphPad 980 
prism. 981 
 982 
 983 
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Figure 6 988 
 989 
 990 
Fig 6: Time-course analysis through IC50 speed assay using unsynchronised 991 
cultures of Plasmodium falciparum: 992 
The graphs show that IC50 values could not be reached within 24 hours. (-)-R,S-993 
dehydroemetine and (-)-S,S-dehydroisoemetine reached the IC50 by 48 hours. Error 994 
bars represent the standard error on the experiments performed twice with each 995 
concentration of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine tested in 996 
triplicates (a) (-)-R,S-dehydroemetine with concentration (25, 50, 100, 200 and 400 997 
nM) at 24h, 48h and 72h, (b) (-)-S,S-dehydroisoemetine with concentration (0.63, 998 
1.25, 2.5, 5 and 10 µM) at 24h, 48h and 72h. 999 
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Figure 7 1007 
 1008 
Fig 7: Stage-specific profiling using synchronised cultures of Plasmodium 1009 
falciparum.  1010 
The decrease in growth of trophozoites/schizonts was observed to be more marked 1011 
in comparison to rings. The drug effects are expressed as a percentage of growth of 1012 
the rings relative to trophozoites/schizonts 24h after the post-exposure wash. Error 1013 
bars represent the standard error on the experiments performed twice with each 1014 
concentration of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine tested in 1015 
triplicates. (a) Cultures were exposed to a serial dilution of (-)-R,S-dehydroemetine 1016 
(from 132.81 nM to 8500 nM) for 24h, (b) Cultures were exposed to a serial dilution 1017 
of (-)-S,S-dehydroisoemetine (from 3.13 µM to 200 µM) for 24h. 1018 
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Figure 8 1026 
 1027 
Fig 8: 48 hour MTT assay  1028 
Cells were seeded at 5000 cells per well. Cell viability was determined using a 1029 
standard MTT assay. Data was analysed using GraphPad prism. Error bars 1030 
represent the standard deviation on the experiments performed thrice with each 1031 
concentration of emetine, cisplatin, (-)-R,S-dehydroemetine and (-)-S,S-1032 
dehydroisoemetine tested in triplicate. (a) 48 hour MTT assay for emetine, tested in 1033 
two-fold serial dilutions from 31.25 nM to 2000 nM, (b) 48 hour MTT assay for 1034 
cisplatin, tested in two-fold serial dilutions from 0.78 µM to 25 µM, (c) 48 hour MTT 1035 
assay for (-)-R,S-dehydroemetine, tested in two-fold serial dilutions from 11.72 nM to 1036 
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750 nM, and (d) 48 hour MTT assay for (-)-S,S-dehydroisoemetine, tested in two-fold 1037 
serial dilutions from 0.312 µM to 10 µM. 1038 
 1039 
Figure 9 1040 
 1041 
Fig 9: Staining of parasites with rhodamine123 and draq5. 1042 
The parasites were stained with rhodamine123 and draq5. Merge with brightfield 1043 
shows localisation of the dye within the parasite. P. falciparum K1 strain trophozoites 1044 
stained with (A) Draq5 10 µM, (B) Rhodamine123 200 nM, (C) Draq5 and 1045 
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Rhodamine merge and (D) Draq5, rhodamine123 and brightfield merge. Visualised 1046 
under fluorescence microscope at 100x magnification 1047 
 1048 
Figure 10 1049 
 1050 
Fig 10: Disruption of mitochondrial membrane potential 1051 
Changes in mitochondrial membrane potential observed on treatment with IC50 of 1052 
atovaquone, emetine and (-)-R,S-dehydroemetine. (a) Graphical representation of 1053 
change in fluorescent intensity on application of drugs at IC50 concentration, (b) 1054 
Table showing changes in fluorescent intensity (FITC-A mean) on application of 1055 
drugs at IC50 and IC50 x 10 concentrations. FITC-A mean of infected blood without 1056 
drugs was considered to be the base value (0) and FITC-A mean of the compounds 1057 
are represented as percentage deviation from the base value. 1058 
 1059 
 1060 
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Figure 11 1061 
 1062 
Fig 11: CalcuSyn-based drug interactivity analysis for atovaquone and 1063 
proguanil.  1064 
(a) CalcuSyn based median effect plot, (b) isobologram, and (c) dose-effect curve 1065 
analysed through GraphPad Prism for drug interactivity between atovaquone and 1066 
proguanil. Atovaquone and proguanil (1:7000) combination was found to be strongly 1067 
synergistic at IC50 (CI = 0.21) and IC75 (CI = 0.34), and synergistic at IC90 (CI = 0.57) 1068 
 1069 
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Figure 12 1073 
 1074 
Fig 12: CalcuSyn-based drug interactivity analysis for (-)-R,S-dehydroemetine - 1075 
atovaquone combination.  1076 
Dose-effect curve analysed through GraphPad Prism for drug interactivity between (-1077 
)-R,S-dehydroemetine and atovaquone. Atovaquone and (-)-R,S-dehydroemetine 1078 
(1:25) combination was found to display slight synergy at IC50 (CI = 0.88), IC75 (CI = 1079 
0.88) and IC90 (CI = 0.89). 1080 
 1081 
 1082 
 1083 
 1084 
 1085 
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 1088 
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Figure 13 1090 
 1091 
Fig 13: CalcuSyn drug interactivity analysis for proguanil and (-)-R,S-1092 
dehydroemetine combination. 1093 
Dose-effect curve analysed through GraphPad Prism for drug interactivity between 1094 
proguanil and (-)-R,S-dehydroemetine. Proguanil and (-)-R,S-Dehydroemetine 1095 
(140:1) combination was found to be synergistic at IC50 (CI = 0.67), nearly additive at 1096 
IC75 (CI = 1.04) and antagonistic at IC90 (CI = 1.62). 1097 
 1098 
 1099 
 1100 
 1101 
 1102 
 1103 
 1104 
 1105 
 1106 
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Figure 14 1107 
 1108 
Fig 14: Synthesis of 2, 3-dehydroemetine. 1109 
Conditions: a) i. iodomethane, ethanol, rt, 24 h, ii. 2, KOAc, reflux, 3 h, 72%; b) 1110 
malononitrile, ammonium acetate/acetic acid, toluene, reflux, 2.5 h, 69%; c) i. 20% 1111 
HCl, reflux, 5 h, ii. methanolic HCl, rt, 18 h, 45%; d. (+)-dibenzoyl tartrate, methanol, 1112 
two recrystallizations, 25%; e) i. 3M HCl, reflux, 90 min, ii. 3,4-1113 
dimethoxyphenethylamine, xylenes, reflux, 18 h, iii. POCl3, benzene, reflux, 1 h, 1114 
28%; f) NaBH4, methanol, rt, 1 h, 81% of a 1:1 diastereomeric mixture. 1115 
7: (S)-2-((R)-6,7-Dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-3-ethyl-9,10-1116 
dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline * dihydrobromide 1117 
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8: (S)-2-((S)-6,7-Dimethoxy-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-3-ethyl-9,10-1118 
dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline * dihydrobromide 1119 
 1120 
Tables: 1121 
 1122 
Table 1: Analysis of results to determine cross-resistance through 3H-1123 
Hypoxanthine incorporation assay 1124 
Compounds 
3D7A Dd2 W2     
Pf 
IC50 
(µM) 
SD 
Pf 
IC50 
(µM) 
SD 
Pf 
IC50 
(µM) 
SD 
ratio 
Dd2/3D7A 
ratio 
W2/3D7a 
Emetine 
dihydrochloride 
0.234 0.022 0.269 0.025 0.181 0 1.15 0.77 
(-)-R,S-
dehydroemetine 
0.146 0.003 0.177 0.014 0.168 0.005 1.21 1.15 
(-)-S,S-
dehydroisoemetine 
1.031 0.041 ND   ND       
 1125 
In-vitro IC50 values of emetine dihydrochloride, (-)-R,S-dehydroemetine and (-)-S,S-1126 
dehydroisoemetine in P. falciparum sensitive strain (3D7A) and P. falciparum 1127 
resistant strains (Dd2 and W2). It also shows the ratios of in-vitro cross-resistance of 1128 
emetine dihydrochloride and (-)-R,S-dehydroemetine in both resistant strains (Dd2 1129 
and W2) using 3D7A strain as reference (SD denotes standard deviation). 1130 
 1131 
 1132 
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Table 2: In-vitro IC50 values of (-)-R,S-dehydroemetine and (-)-S,S-1133 
dehydroisoemetine against male and female gametocytes in P. falciparum 1134 
NF54 strain 1135 
  
P. falciparum Dual Gamete Formation 
Assay 
Male Female 
Compounds Average    SD Average    SD 
(-)-R,S-dehydroemetine (µM) 0.43 0.02 1.04 0.02 
(-)-S,S-dehydroisoemetine (µM) >10   >10   
 1136 
In-vitro IC50 values of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine against 1137 
male and female gametocytes in P. falciparum NF54 strain. 1138 
 1139 
Table 3: hERG channel inhibition assay results for (-)-R,S-dehydroemetine and 1140 
(-)-S,S-dehydroisoemetine 1141 
Cyprotex hERG channel inhibition (IC50 determination) 
Compounds 
% Mean inhibition 
0 
µM 
0.016 
µM 
0.08 
µM 
0.4 
µM 
2 
µM 
10 
µM 
50 
µM 
IC50 (µM) 
(-)-R,S-dehydroemetine 0 7.79 6.34 12.7 7.21 39.4 61.4 19.3 
(-)-S,S-dehydroisoemetine 0 8.13 4.61 9.33 36 70.7 96.9 2.99 
 1142 
Effect of (-)-R,S-dehydroemetine and (-)-S,S-dehydroisoemetine determined using 1143 
hERG channel inhibition assay. Each value is a mean of triplicate values. 1144 
 1145 
 1146 
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Table 4: The dose series used for the combination of existing antimalarials 1147 
(AM) with (-)-R,S-dehydroemetine 1148 
Level (-)-R,S-dehydroemetine (nM)  Atovaquone (nM) Proguanil (µM) 
A 12.5 0.5 1.75 
B 25 1 3.5 
C 50 2 7 
D 100 4 14 
E 200 8 28 
F 400 16 56 
G 800 32 112 
Combination ratio 
with (-)-R,S-
dehydroemetine 
                       -- 
             1:25       140:1 
 1149 
 1150 
Table 5: CalcuSyn-based drug interaction analysis 1151 
Drug interaction 
Combination Index 
values (CI) r 
ED50 ED75 ED90 
Atovaquone and Proguanil 
(1:7000) 0.21 0.34 0.57 0.93 
Atovaquone and (-)-R,S-
dehydroemetine (1:25) 0.88 0.88 0.89 0.96 
Proguanil and (-)-R,S-
dehydroemetine (140:1) 0.67 1.04 1.62 0.95 
 1152 
The combination ratios and CalcuSyn determined Combination Index (CI) values for 1153 
the assays performed. The r value represents the linear correlation coefficient for the 1154 
median effect plot and indicates conformity to the mass action law. 1155 
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Table 6: Classification of synergism or antagonism using CI values generated 1156 
by Chou-Talalay method (Source: CalcuSyn manual, Biosoft, 2006) 1157 
Range of CI Symbol Description 
<0.1 +++++ Very strong synergism 
0.1-0.3 ++++ Strong synergism 
0.3-0.7 +++ Synergism 
0.7-0.85 ++ Moderate synergism 
0.85-0.90 + Slight synergism 
0.90-1.10 + Nearly additive 
1.10-1.20 - Slight antagonism 
1.20-1.45 -- Moderate antagonism 
1.45-3.3 --- Antagonism 
3.3-10 ---- Strong antagonism 
>10 ----- Very strong antagonism 
 1158 
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